Bank of America Merrill Lynch Maintains Buy on St. Jude Medical

Bank of America Merrill Lynch is out with its report today on St. Jude Medical STJ, maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "STJ trades at no meaningful premium to the group despite what we view as a solidly superior growth outlook on the top and bottom lines. Going forward we believe STJ should maintain 8-10% organic CC growth with significant opportunities for leverage even in a more difficult pricing environment. STJ remains one of our top ideas in large cap medtech. At the time of posting, shares of STJ were trading at $50.50, up 0.62% from Thursday's close.